Publications found:
73,128
Sort by:
DISHMAN - Result Does Not Change the Outlook
US$ 140.00
Dishman’s Q3 FY12 EBITDA was higher than our estimates owing to change in ... and Dishman Netherlands grew by 28% and 36% Y-o-Y respectively mainly due to a favorable forex. Carbogen remained flat in constant currency. In other words, this quarter does not ...
February 2012
5 pages
GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!
US$ 140.00
Gilead (GILD) is poised for further growth, based on the FY12 ... GILD a step closer towards its goal to deliver the “best-in-class IFN-free oral pill” for HCV. Other acquisitions ... read our report released on 10th Feb., 2012 on Gilead Sciences titled “Providing the Best Antiviral Treatment Options for HIV and HCV!”
February 2012
11 pages
Indian Healthcare - New Avenues for Growth
US$ 800.00
In India, delivering an affordable healthcare to billion-plus population presents enormous challenges and opportunities for the medical community. The past decade has seen the country’s healthcare sec...
February 2012
90 pages
India Commercial Vehicle Market Analysis
US$ 800.00
Two decades ago, India opened its doors for multinational automobile companies allowing them to penetrate the market, modernize the Indian transportation picture and make it beneficial for the end-use...
February 2012
80 pages
Gene Therapy: Market Research Report
US$ 4,500.00
This report analyzes the Global market for Gene Therapy in US$ Million. Annual estimates and forecasts are provided for the period 2009 through ... GenVec, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd., Transgene, and Vical Inc. Market data and analytics are derived from primary and secondary research. ...
February 2012
459 pages
Gums: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Gums in US$ Million by the following Product Segments: Chewing Gum, and Bubble Gum. The report provides separate ... 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 126 companies including many key and niche ...
February 2012
304 pages
Tiered Pricing Strategies in Emerging Markets
US$ 695.00
For the pharmaceutical industry, emerging markets are dynamic, full of potential and offer solid growth at a time when established markets are contracting. But they also pose a significant problem: ex...
February 2012
93 pages
IPCA - Awaiting Re-rating
US$ 140.00
... visibility in sales growth and margin improvement, the stock simply awaits re-rating. Going forward, earnings will be driven by (1) domestic market ... and FY13 earnings by 5-6%. At current valuation, IPCA trades at a PE of 10x on FY13 earnings. This makes IPCA the cheapest stock available with a sustainable ...
January 2012
5 pages
ROCHE - Erivedge (Vismodegib) approved for Locally Advanced or Metastatic BCC in US
US$ 90.00
... , ROG and Curis jointly announced that the USFDA approved once daily Erivedge, oral, first in class hedgehog inhibitor earlier than ... to be approved for this indication. Erivedge will be available in specialty pharmacies in US within one or two weeks. Roche has the marketing rights for Vismodegib excluding ...
January 2012
5 pages
BMY 4Q-11 Results – Patent expiry pains reflecting in the guidance
US$ 90.00
Post today’s announcement of 4Q-11 results, we reiterate our underperform rating on BMY with a PT of $26. The 2012 EPS guidance range of $1.9 - $2.0 is ... reflective of the towering pressures, while valuation continues to remain soaring. BMY holds a promising HCV pipeline, but seems priced to perfection. Yeryoy ...
January 2012
1 pages
NOVARTIS
US$ 90.00
For the fourth quarter 2011, in line with our expectations, NVS Sales grew 5%, and core EPS advanced 8%. NVS also announced full year dividend for 2011 at CHF 2.25, which translates into a meager 2%, increase, which we think is a dampener. The 2012 guidance as well was lackluster as NVS expects net sales in ...
January 2012
2 pages
Global Telemedicine Market Analysis
US$ 1,200.00
Telemedicine enables in providing interactive healthcare utilizing modern technology and telecommunication. The global telemedicine industry has been growing stupendously over the past few years with...
January 2012
65 pages
Global Cosmeceuticals Market Analysis
US$ 1,400.00
Cosmeceuticals are the latest addition to the health industry and are described as cosmetic products with drug-like benefits. With the rise of more knowledgeable, wealthy, and beauty-conscious class o...
January 2012
70 pages
REGENERON – Eylea Sales Add a Sparkle to The Eye!
US$ 120.00
... and Avastin (off-label), Regeneron (REGN) overwhelmed all concerns of a “weak launch” of Eylea (VEGF Trap-Eye, L, ... Bill” model! Uptake at this pace should entitle Eylea to capture…. Moreover, CEO’s optimism around REGN’s ... released on 11th January, 2012 on Regeneron titled “Eylea Sales Add a Sparkle to The Eye!”
January 2012
6 pages
REGENERON - Eylea’s Litigation Settlement = Good Start to 2012!
US$ 90.00
Regeneron (REGN) settled its patent litigation with Genentech (Roche) over Eylea (VEGF Trap-Eye, L, partnered ... payments to Roche -$60m when cumulative US sales of Eylea reach $400m + will pay royalties of 4.75% on ... 6th January, 2012 on Regeneron titled “Eylea’s Litigation Settlement = Good Start to 2012!”
January 2012
6 pages
Global Endoscopy Market Report: 2011 Edition
US$ 800.00
... report presents an analysis of the global endoscopy market. It begins with a discussion of the worldwide medical equipment and supplies market and then goes on to analyze the global endoscopy equipment market ...
January 2012
32 pages
Managed Health Care Services: Market Research Report
US$ 1,995.00
The global outlook series on Managed Health Care Services provides anecdotes, market briefs, and concise summaries of research findings. The report analyzes the growth drivers and market challenges, and reviews the noteworthy strategic corporate activity of the recent past. The ...
January 2012
79 pages
Hospitals: Market Research Report
US$ 1,450.00
The global outlook series on Hospitals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. Illustrated with 42 fact-rich market data tables, the report offers insight into the industry’s performance in the wake of an expanding global population, rising ...
January 2012
353 pages
Home Health Care Services: Market Research Report
US$ 1,995.00
The global outlook series on Home Health Care Services provides a collection of statistical findings, market briefs, and concise summaries of research findings. Amply illustrated with 24 market data, tables, charts, and graphs, the report offers a rudimentary overview of the industry, highlights latest ...
January 2012
102 pages
Oxygen Therapy: Market Research Report
US$ 1,995.00
... anecdotes, market briefs, and concise summaries of research findings. The report offers an aerial view of the global oxygen therapy industry, identifies major short to medium term market challenges, and growth drivers. Regional markets elaborated upon include United States ...
January 2012
70 pages
Health Spas: Market Research Report
US$ 1,995.00
The global outlook series on Health Spas provides a collection of statistical findings, market briefs, and concise summaries of research findings. Market discussions in the report are amply illustrated with 57 fact-rich market data tables, charts, and graphs. Regions covered include United States, ...
January 2012
112 pages
Alternative Medicine: Market Research Report
US$ 1,995.00
The global outlook series on the Alternative Medicine Industry provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. Illustrated with 31 fact-rich market data tables, the report offers a rudimentary overview of the industry, and highlights latest trends ...
January 2012
148 pages
Emergency and Other Relief Services: Market Research Report
US$ 1,995.00
The global outlook series on Emergency and Other Relief Services provides a collection of statistical anecdotes, market briefs, and concise summaries of research ... , Canada, Japan, Australia, China, India and New Zealand, among others. Also included is an indexed, easy-to-refer, fact-finder directory listing ...
January 2012
70 pages
Healthcare Services: Market Research Report
US$ 1,450.00
The global outlook series on Healthcare Services provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report details the prevailing situation in the world healthcare delivery system, and provides extensive coverage of all the recent mergers, and ...
January 2012
94 pages
Digital Health Quarterly 1Q 2012 2Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2012
16 pages
Digital Health Quarterly 2Q 2012 3Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2012
16 pages
Digital Health Quarterly 3Q 2012 4Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2012
18 pages
Digital Health Quarterly 4Q 2011 1Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
January 2012
17 pages
Health Entertainment: Bringing the Fun to Wellness and Fitness 3Q 2012
US$ 3,500.00
This report analyzes the intersection of the entertainment world with human health and well being. It defines this unique industry sector with ... -user revenues. "Health entertainment is a perfect example of technology’s imprint on the science of human behavioral changes," said Harry Wang, Director of Mobile & Health Research at Parks ...
January 2012
55 pages
Para IV pluse Subscriptions
US$ 4,500.00
Para IV Plus is a knowledge bank of ongoing pharma patent litigations covered in the most comprehensive manner. Currently it covers ~400 product patent litigations – i.e. ALL the patent litigations involving global as well as non global innovator companies.
December 2011
-
Global HIV Therapeutics Market Analysis
US$ 1,200.00
HIV endemic has had devastating economic, social, health and psychological impacts over the years affecting millions of households in a significant manner over the last decade. Despite the concrete ef...
December 2011
70 pages
Global Regenerative Medicine Market
US$ 1,200.00
Regenerative medicine is an emerging interdisciplinary field that spans tissue engineering, stem-cell biology, nanoscience, and bioengineering for the repair of cells, tissues and organs. It seeks to...
December 2011
105 pages
US Healthcare Market Outlook 2013
US$ 1,000.00
The US represents the world’s largest healthcare market, with a high annual healthcare spending. The growth in healthcare spending is mainly driven by high administrative costs, and expensive hospital...
December 2011
80 pages
Outlook 2012 - Rising Stars - Innovators Deliver but Rewards Not Guranteed!
US$ 2,000.00
... continue to flow from the backyards of small research focused companies (Rising stars, RS) but commercial success of launched products is not assured despite patents ... Micromet (MITI) are our Top Picks for FY2012 in the Rising Stars Sector. Key drugs of ANTH and MITI target high unmet ...
December 2011
52 pages
Competitor Analysis: HIV Small Molecule Therapeutics
US$ 642.00
The present Competitive Intelligence report about HIV Small Molecule Therapeutics used to treat human immunodeficiency virus (HIV) infections provides a competitor evaluation in the field of marketed...
December 2011
100 pages
NOVARTIS - Tekturna: ALTITUDE study in high risk hypertensive patients TERMINATED
US$ 90.00
... the termination of large PhIII study (ALTITUDE) due to higher rate of adverse events and no benefits observed for patients taking Tekturna in addition to ACE ... inhibitors. Post this announcement, NVS will cease promotion of Tekturna/Tekturna products in combination with ACE inhibitors/ARB inhibitors. The event ...
December 2011
1 pages
LUPIN - Lupin - Loss of 2 Exclusivities Further Exposes the weak Pipeline
US$ 140.00
... . Most glaring is the Fortmet case, where Lupin launched the product ‘at-risk’ and later withdrew ... settled with Lupin it cannot launch its generic version (unless ‘at-risk’) thereby leading to a loss of this ... shared 180-day exclusivity for Lupin. These add to the pressure ...
December 2011
3 pages
